These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34185201)

  • 1. Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD.
    Sardana O; Goyal R; Bedi O
    Inflammopharmacology; 2021 Aug; 29(4):1061-1074. PubMed ID: 34185201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression.
    Ochi A; Mori K; Emoto M; Nakatani S; Morioka T; Motoyama K; Fukumoto S; Imanishi Y; Koyama H; Ishimura E; Inaba M
    PLoS One; 2014; 9(2):e88704. PubMed ID: 24551137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies.
    Haukeland JW; Dahl TB; Yndestad A; Gladhaug IP; Løberg EM; Haaland T; Konopski Z; Wium C; Aasheim ET; Johansen OE; Aukrust P; Halvorsen B; Birkeland KI
    Eur J Endocrinol; 2012 Mar; 166(3):503-10. PubMed ID: 22170794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fetuin A is a Predictor of Liver Fat in Preoperative Patients with Nonalcoholic Fatty Liver Disease.
    von Loeffelholz C; Horn P; Birkenfeld AL; Claus RA; Metzing BU; Döcke S; Jahreis G; Heller R; Hoppe S; Stockmann M; Lock JF; Rieger A; Weickert MO; Settmacher U; Rauchfuß F; Pfeiffer AF; Bauer M; Sponholz C
    J Invest Surg; 2016 Oct; 29(5):266-74. PubMed ID: 26980291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fetuin-A in newly detected type 2 diabetes mellitus as a marker of non-alcoholic fatty liver disease.
    Yamasandhi PG; Dharmalingam M; Balekuduru A
    Indian J Gastroenterol; 2021 Dec; 40(6):556-562. PubMed ID: 34950996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies.
    Zhang CH; Zhou BG; Sheng JQ; Chen Y; Cao YQ; Chen C
    Pharmacol Res; 2020 Sep; 159():104984. PubMed ID: 32502637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans.
    Peter A; Kovarova M; Staiger H; Machann J; Schick F; Königsrainer A; Königsrainer I; Schleicher E; Fritsche A; Häring HU; Stefan N
    Am J Physiol Endocrinol Metab; 2018 Mar; 314(3):E266-E273. PubMed ID: 29138227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease.
    Celebi G; Genc H; Gurel H; Sertoglu E; Kara M; Tapan S; Acikel C; Karslioglu Y; Ercin CN; Dogru T
    Saudi J Gastroenterol; 2015; 21(3):139-45. PubMed ID: 26021772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Zhang LY; Qu XN; Sun ZY; Zhang Y
    Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):674-680. PubMed ID: 32113823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
    Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
    Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose.
    Ou HY; Yang YC; Wu HT; Wu JS; Lu FH; Chang CJ
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4717-23. PubMed ID: 23066121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.
    Moradi F; Kooshki F; Nokhostin F; Khoshbaten M; Bazyar H; Pourghassem Gargari B
    J Trace Elem Med Biol; 2021 Jan; 63():126659. PubMed ID: 33045675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fetuin-A: a novel link between obesity and related complications.
    Trepanowski JF; Mey J; Varady KA
    Int J Obes (Lond); 2015 May; 39(5):734-41. PubMed ID: 25468829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease.
    Pampanini V; Inzaghi E; Germani D; Alterio A; Puglianiello A; Alisi A; Nobili V; Cianfarani S
    Nutr Metab Cardiovasc Dis; 2018 Jan; 28(1):71-76. PubMed ID: 29122442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart.
    Dogru T; Kirik A; Gurel H; Rizvi AA; Rizzo M; Sonmez A
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance.
    Ou HY; Wu HT; Hung HC; Yang YC; Wu JS; Chang CJ
    Endocrinology; 2012 Jul; 153(7):2974-84. PubMed ID: 22619360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
    Shaaban HH; Alzaim I; El-Mallah A; Aly RG; El-Yazbi AF; Wahid A
    Life Sci; 2022 Nov; 308():120956. PubMed ID: 36103959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease.
    Dogru T; Genc H; Tapan S; Aslan F; Ercin CN; Ors F; Kara M; Sertoglu E; Karslioglu Y; Bagci S; Kurt I; Sonmez A
    Clin Endocrinol (Oxf); 2013 May; 78(5):712-7. PubMed ID: 22676641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects.
    Sato M; Kamada Y; Takeda Y; Kida S; Ohara Y; Fujii H; Akita M; Mizutani K; Yoshida Y; Yamada M; Hougaku H; Takehara T; Miyoshi E
    Liver Int; 2015 Mar; 35(3):925-35. PubMed ID: 25627311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A.
    Jung TW; Youn BS; Choi HY; Lee SY; Hong HC; Yang SJ; Yoo HJ; Kim BH; Baik SH; Choi KM
    Biochem Pharmacol; 2013 Oct; 86(7):960-9. PubMed ID: 23948064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.